source
- Boston Scientific cuts guidance again after unveiling restructuring planBoston Scientific is cutting its financial guidance for the second quarter in a row as it gears up for a tough six months ahead.Fierce Biotech · 17h ago↗ source
- FDA advisory panel rejects Capricor’s Duchenne cardiomyopathy cell therapyA FDA advisory committee voted against Capricor’s cell therapy for Duchenne muscular dystrophy cardiomyopathy, with nine members opposing and three supporting the product. The therapy, called dera…